DOCSLIB.ORG

Citi Pure Earnings Growth US Long-Short Net TR Index (CIISGRUN)

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

Date: 20-Aug-21 Index Weights as of monthly rebalance date 10-Aug-21 Citi Pure Earnings Growth US Long-Short Net TR Index (CIISGRUN) Long Exposure Short Exposure Constituent Bloomberg Ticker Constituent Name Weight(%) Constituent Bloomberg Ticker Constituent Name Weight(%) 1 AAP UN Equity Advance Auto Parts Inc 0.24% 1 A UN Equity Agilent Technologies Inc -0.12% 2 ABBV UN Equity AbbVie Inc. 0.59% 2 HWM UN Equity Alcoa Inc -1.02% 3 ABC UN Equity AmerisourceBergen Corp 0.06% 3 AAL UW Equity American Airlines Group Inc -1.09% 4 ADBE UW Equity Adobe Systems Inc 0.01% 4 AAPL UW Equity Apple Inc. -0.46% 5 ADM UN Equity Archer-Daniels-Midland Co 0.26% 5 ABMD UW Equity ABIOMED Inc -0.11% 6 ADSK UW Equity Autodesk Inc 0.26% 6 ABT UN Equity Abbott Laboratories -0.26% 7 AES UN Equity AES Corp 0.37% 7 CB UN Equity ACE Limited -0.07% 8 AIG UN Equity American Intl Group Inc 0.52% 8 ACN UN Equity Accenture plc -0.29% 9 AIZ UN Equity Assurant Inc 0.11% 9 ADI UW Equity Analog Devices Inc -0.13% 10 ALGN UW Equity Align Technology Inc 0.59% 10 ADP UW Equity Automatic Data Processing -0.76% 11 ALL UN Equity Allstate Corp 0.16% 11 AEE UN Equity Ameren Corp -0.24% 12 ALLE UN Equity Allegion PLC 0.34% 12 AEP UW Equity American Electric Power -0.23% 13 AMAT UW Equity Applied Materials Inc 0.59% 13 AFL UN Equity AFLAC Inc -0.29% 14 AMD UW Equity Advanced Micro Devices Inc 1.15% 14 AJG UN Equity ARTHUR J GALLAGHER & CO -0.23% 15 AME UN Equity AMETEK Inc 0.26% 15 AKAM UW Equity Akamai Technologies Inc -0.11% 16 AMT UN Equity American Tower Corp A 0.39% 16 ALB UN Equity Albemarle Corp -0.14% 17 AMZN UW Equity Amazon.com Inc 1.34% 17 ALK UN Equity Alaska Air Group Inc -1.17% 18 AOS UN Equity SMITH (A.O.) CORP 0.26% 18 AMCR UN Equity Amcor PLC -0.86% 19 APA UW Equity Apache Corp 0.72% 19 AMGN UW Equity Amgen Inc -0.31% 20 ARE UN Equity Alexandria Real Estate Eqty 0.78% 20 AMP UN Equity Ameriprise Financial Inc -0.22% 21 ATVI UW Equity Activision Blizzard Inc 0.51% 21 ANET UN Equity ARISTA NETWORKS INC -0.18% 22 AVGO UW Equity Avago Technologies Ltd 0.43% 22 ANSS UW Equity ANSYS Inc -0.02% 23 AVY UN Equity Avery Dennison Corp 0.01% 23 AON UN Equity Aon Corp -0.49% 24 AWK UN Equity American Water Works Co Inc 0.10% 24 APD UN Equity Air Products & Chemicals Inc -0.40% 25 AZO UN Equity AutoZone Inc 0.21% 25 APH UN Equity Amphenol Corp A -0.18% 26 TFC UN Equity BB&T Corp 0.49% 26 ATO UN Equity Atmos Energy Corp -0.18% 27 BEN UN Equity Franklin Resources Inc 0.26% 27 AVB UN Equity AvalonBay Communities Inc -0.52% 28 BF/B UN Equity Brown-Forman Corp B 0.08% 28 AXP UN Equity American Express Co -0.37% 29 BKR UN Equity Baker Hughes Inc 0.22% 29 BA UN Equity Boeing Co -0.51% 30 BIO UN Equity Bio-Rad Laboratories Inc 0.59% 30 BAC UN Equity Bank of America Corp -0.30% 31 BLL UN Equity Ball Corp 0.15% 31 BAX UN Equity Baxter Intl Inc -0.70% 32 BMY UN Equity Bristol-Myers Squibb 0.80% 32 BBY UN Equity Best Buy Co Inc -0.19% 33 BSX UN Equity Boston Scientific Corp 0.04% 33 BDX UN Equity BECTON DICKINSON AND CO -0.58% 34 BWA UN Equity Borgwarner Inc 0.37% 34 BIIB UW Equity Biogen Idec Inc -0.72% 35 BXP UN Equity Boston Properties Inc 0.29% 35 BK UN Equity The Bank of New York Mellon Corp -0.52% 36 CAG UN Equity ConAgra Foods Inc 0.28% 36 BLK UN Equity BlackRock Inc -0.14% 37 CARR UN Equity CARRIER GLOBAL CORP 0.41% 37 BR UN Equity Broadridge Financial Solutions Inc. -0.19% 38 CBRE UN Equity CBRE GROUP INC - A 0.64% 38 BRK/B UN Equity Berkshire Hathaway B -0.85% 39 CBOE UF Equity CBOE Holdings Inc 0.55% 39 CAH UN Equity Cardinal Health Inc -0.56% 40 CCI UN Equity CROWN CASTLE INTL CORP 0.20% 40 CAT UN Equity Caterpillar Inc -0.36% 41 CDNS UW Equity Cadence Design Systems Inc 0.25% 41 VIAC UW Equity CBS Corp B -0.33% 42 CDW UW Equity CDW Corp/DE 0.02% 42 CCL UN Equity Carnival Corp -1.39% 43 CERN UW Equity Cerner Corp 0.15% 43 CE UN Equity Celanese Corp A -0.39% 44 CF UN Equity CF Industries Holdings 0.01% 44 CINF UW Equity Cincinnati Financial Corp -0.21% 45 CFG UN Equity Citizens Financial Group Inc 0.45% 45 CL UN Equity Colgate-Palmolive Co -0.13% 46 CHD UN Equity Church & Dwight Co 0.08% 46 CLX UN Equity Clorox Co -0.20% 47 CHRW UW Equity CH Robinson Worldwide Inc 0.09% 47 CMA UN Equity Comerica Inc (MI) -0.39% 48 CHTR UW Equity Charter Communications Inc 0.91% 48 CMCSA UW Equity Comcast Corp -0.07% 49 CI UN Equity Cigna Corporation 0.01% 49 CME UW Equity Chicago Mercantile Exchange -1.05% 50 CMG UN Equity Chipotle Mexican Grill Inc. 0.39% 50 CMI UN Equity Cummins Inc -0.23% 51 CNC UN Equity Centene Corp 0.88% 51 CMS UN Equity CMS Energy Corp -0.02% 52 COG UN Equity Cabot Oil & Gas A 0.16% 52 CNP UN Equity Centerpoint Energy Inc -0.52% 53 COP UN Equity ConocoPhillips 0.11% 53 COF UN Equity Capital One Financial -0.56% 54 COST UW Equity Costco Wholesale Corp 0.19% 54 TPR UN Equity Tapestry Inc -1.08% 55 CPRT UW Equity Copart Inc 0.64% 55 COO UN Equity Cooper Companies Inc -0.35% 56 CRL UN Equity Charles River Laboratories 0.64% 56 CPB UN Equity Campbell Soup Co -0.12% 57 CRM UN Equity Salesforce.com 0.15% 57 CSCO UW Equity Cisco Systems Inc -1.07% 58 CTAS UW Equity Cintas Corp 0.76% 58 CSX UW Equity CSX Corp -0.08% 59 LUMN UN Equity CenturyLink Inc 0.00% 59 CTSH UW Equity Cognizant Tech Solutions Corp -0.33% 60 CTLT UN Equity Catalent Inc 0.57% 60 CTXS UW Equity Citrix Systems Inc -0.30% 61 CTVA UN Equity Corteva Inc 0.37% 61 CVS UN Equity CVS Caremark Corp. -0.42% 62 DE UN Equity Deere & Co 0.07% 62 CVX UN Equity Chevron Corp -0.21% 63 DG UN Equity Dollar General Corp 0.21% 63 D UN Equity Dominion Resources Inc -0.45% 64 DHI UN Equity DR HORTON INC 0.97% 64 DAL UN Equity Delta Air Lines -1.38% 65 DHR UN Equity Danaher Corp 0.26% 65 DFS UN Equity Discover Financial Services -0.09% 66 DISH UW Equity DISH Network Corp 0.30% 66 DGX UN Equity Quest Diagnostics -0.08% 67 DLR UN Equity Digital Realty Trust 0.01% 67 DIS UN Equity Walt Disney Co -0.60% 68 DOW UN Equity Dow Inc 0.31% 68 DISCK UW Equity Discovery Communications Inc -0.19% 69 DPZ UN Equity Domino's Pizza Inc 0.55% 69 APTV UN Equity Aptiv Plc -0.53% 70 DTE UN Equity DTE Energy Co 0.11% 70 DLTR UW Equity Dollar Tree Inc -0.19% 71 DVA UN Equity Davita Inc 0.16% 71 DOV UN Equity Dover Corp -0.32% 72 DVN UN Equity Devon Energy Corp 0.60% 72 DD UN Equity Dow Chemical -0.85% 73 DXCM UW Equity DexCom Inc 1.01% 73 DRE UN Equity Duke Realty Corp -0.41% 74 EA UW Equity Electronic Arts 0.09% 74 DRI UN Equity Darden Restaurants Inc -0.11% 75 EFX UN Equity Equifax Inc 0.01% 75 DUK UN Equity Duke Energy Corp -0.32% 76 EIX UN Equity Edison Intl 0.38% 76 DXC UN Equity DXC Technology Co -0.97% 77 ENPH UQ Equity ENPHASE ENERGY INC 0.78% 77 EBAY UW Equity eBay Inc. -0.28% 78 EOG UN Equity EOG Resources 0.85% 78 ECL UN Equity Ecolab Inc -0.52% 79 EQIX UW Equity Equinix Inc 0.81% 79 ED UN Equity Consolidated Edison Inc -0.04% 80 CZR UW Equity Eldorado Resorts Inc 1.44% 80 EL UN Equity Estee Lauder Cos. -0.19% 81 ESS UN Equity Essex Property Trust 0.19% 81 EMN UN Equity Eastman Chemical Co -0.08% 82 ETR UN Equity Entergy Corp 0.02% 82 EMR UN Equity Emerson Electric Co -0.29% 83 ETSY UW Equity Etsy Inc 1.69% 83 EQR UN Equity Equity Residential -0.50% 84 EXC UW Equity Exelon Corp 0.31% 84 ETN UN Equity Eaton Corp -0.19% 85 EXPD UW Equity Expeditors Intl of WA Inc 0.51% 85 EW UN Equity Edwards Lifesciences Corp -0.06% 86 EXR UN Equity Extra Space Storage Inc 0.38% 86 EXPE UW Equity Expedia -0.96% 87 FANG UW Equity Diamondback Energy Inc 1.62% 87 F UN Equity Ford Motor Co -0.02% 88 FAST UW Equity Fastenal Co 0.17% 88 FIS UN Equity Fidelity National Information -0.41% 89 FB UW Equity Facebook Inc 0.81% 89 FLT UN Equity FleetCor Technologies Inc -0.32% 90 FBHS UN Equity Fortune Brands Home & Security Inc 0.84% 90 FOX UW Equity Fox Corp -0.63% 91 FCX UN Equity Freeport McMoRan Copper & Gold 0.85% 91 FOXA UW Equity Fox Corp -0.21% 92 FDX UN Equity FedEx Corp 0.62% 92 FRT UN Equity Federal Realty Invt Trust -0.43% 93 FE UN Equity FirstEnergy Corp 0.13% 93 FTV UN Equity Fortive Corp -0.85% 94 FFIV UW Equity F5 Networks Inc 0.03% 94 GD UN Equity General Dynamics -0.26% 95 FISV UW Equity Fiserv Inc 0.47% 95 GE UN Equity General Electric Co -0.34% 96 FITB UW Equity Fifth Third Bancorp (OH) 0.18% 96 GILD UW Equity Gilead Sciences Inc -0.12% 97 FMC UN Equity FMC Corp 0.05% 97 GIS UN Equity General Mills Inc -0.35% 98 FRC UN Equity First Republic Bank 0.10% 98 GLW UN Equity Corning Inc -0.20% 99 FTNT UW Equity Fortinet Inc 0.05% 99 GM UN Equity General Motors Company -0.33% 100 IR UN Equity Gardner Denver Holdings Inc 1.57% 100 GPC UN Equity Genuine Parts Co -0.64% 101 GNRC UN Equity Generac Holdings Inc 1.06% 101 GPS UN Equity Gap Inc -0.59% 102 GOOG UW Equity GOOGLE INC-CL C 0.79% 102 GRMN UW Equity Garmin Ltd -0.04% 103 GOOGL UW Equity GOOGLE INC-CL A 0.53% 103 HAL UN Equity Halliburton Co -0.67% 104 GPN UN Equity Global Payments Inc 0.81% 104 HAS UW Equity Hasbro Inc -0.03% 105 GS UN Equity Goldman Sachs Group Inc 0.40% 105 HBI UN Equity Hanesbrands Inc -0.07% 106 GWW UN Equity WW GRAINGER INC 0.17% 106 HCA UN Equity HCA Holdings Inc -0.44% 107 HBAN UW Equity Huntington Bancshares (OH) 0.20% 107 WELL UN Equity Welltower Inc -1.02% 108 HD UN Equity Home Depot Inc 0.13% 108 PEAK UN Equity HCP Inc -0.18% 109 HES UN Equity Hess Corp 0.29% 109 HLT UN Equity HILTON WORLDWIDE HLDGS INC COM -0.44% 110 HIG UN Equity Hartford Finl Services Group 0.06% 110 HOLX UW Equity Hologic Inc -0.17% 111 HII UN Equity HUNTINGTON INGALLS INDUSTRIE 0.48% 111 HON UW Equity Honeywell Intl Inc -0.53% 112 HPE UN Equity HEWLETT PACKARD ENTERPRIS 0.07% 112 HRL UN Equity
Recommended publications
  • Amgen and Incyte – the Biotechnology Acquisition

    Amgen and Incyte – the Biotechnology Acquisition

    Amgen and Incyte – the biotechnology acquisition Ana Carolina Coelho Student number: 152416013 Dissertation written under the supervision of António Luís Borges de Assunção Dissertation submitted in partial fulfilment of requirements for the MSc in Finance, at the Universidade Católica Portuguesa, May 2018 Abstract The main goal of this dissertation is to study the hypothesis of an acquisition in the biotechnology industry, between Amgen (acquirer) and Incyte (target). Amgen is a U.S.-based biotechnology company currently facing a decrease in sales, mainly due to an increase in the market share of generic drugs and the rise of biosimilar products. To offset the poor performance, it is looking for an acquisition in its industry, for which Incyte could be a suitable target. Incyte belongs to the U.S.-biotechnology industry, and although it has a shy presence in the market with only two released drugs, its revenues are expected to increase significantly in the near future. The combination of these companies would allow knowledge transfer about research and development process of new drugs, a stronger position in Europe, and a higher investment power to apply in R&D. The combined company would be able to decrease the number of employees due to duplication of jobs and decrease the cost of sales, as the power over suppliers increases. The potential synergies are valued at $28,522.8 million, of which $16,739.2 million are more likely to be realized. The combined firm, after the introduction of synergies, is expected to generate the same or even higher returns than the sum of the stand- alone businesses and higher growth rates, fulfilling Amgen’s need of growth.
  • Paychex at a Glance

    Paychex at a Glance

    Paychex at a Glance The Future of Work is Here The workplace as we know it is changing. Paychex Facts Paychex leads the way by making complex HR, Founded 1971 — B. Thomas Golisano payroll, and benefits simple. Our innovative HR $4 billion in revenue outsourcing technology and the expertise of our highly trained HR consultants meet the evolving 680,000 business clients — in the U.S. and Europe needs of our clients and their employees. You can see it in our growth as an HR leader as 117,000 clients — with Paychex more than a decade well as in the positive returns we deliver to our shareholders. Paying 12 million workers — one in 12 U.S. private sector employees $750+ billion transferred — each year, and Total Revenue ($Millions) growing For the fiscal year ended May 31 ~16,000 Paychex employees — serving in more than 100 locations 2020 $4,041 600+ dedicated HR consultants — the most in 2019 $3,773 the HR outsourcing industry 2018(1) $3,378 2nd largest PEO — Serving 1.4M worksite employees through our HR outsourcing solutions 2017(1) $3,153 (ASO and PEO) 2016 $2,952 Fiscal year — June 1 through May 31 Headquarters — 911 Panorama Trail S., Rochester, New York 14625 Operating Income ($Millions) For the fiscal year ended May 31 President and CEO — Martin Mucci, since 2010 2020 $1,461 2019 $1,371 2018(1) $1,292 $ % 2017(1) $1,254 889M 41 Dividends Paid Return on Equity 2016 $1,147 1 Amounts for fiscal years 2018 and 2017 have been adjusted to reflect the adoption of the FASB Accounting Standards Codification™, Revenue From Contracts With Clients (Topic 606) to conform with current year presentation.
  • Inozyme Pharma Expands Medical Leadership Team

    Inozyme Pharma Expands Medical Leadership Team

    Inozyme Pharma Expands Medical Leadership Team Strengthens Inozyme’s Ability to Advance Lead Candidate, INZ-701, into Clinical Trials Boston, Mass., Nov. 14, 2019 – Inozyme Pharma Inc., a biotechnology company developing novel medicines to treat rare and life-threatening mineralization disorders, today announced the addition of three industry veterans to its leadership team: • Pedro Huertas M.D., Ph.D., as Chief Medical Officer, • Gus Khursigara Ph.D., as Vice President of Medical Affairs and Clinical Operations, and • Catherine Nester, as Vice President of Physician and Patient Strategies. The executives will be instrumental in advancing Inozyme’s lead drug candidate, INZ-701, into clinical trials in 2020 for the treatment of patients with ENPP1 deficiency. INZ-701 is the first therapy that addresses the pathology of ENPP1 deficiency, including diseases such as generalized arterial calcification of infancy (GACI) type 1 and autosomal recessive hypophosphatemic rickets type 2 (ARHR2), both of which are rare and life-threatening manifestations of this enzyme deficiency. Inozyme Pharma received orphan drug designation for INZ-701 in the US and EU in 2018. “We are pleased and excited to welcome Pedro, Gus and Catherine to the Inozyme team,” said Axel Bolte, co-founder and chief executive officer of Inozyme. “Their expertise in orphan drug development – spanning medical affairs, regulatory affairs and clinical development – will strengthen and accelerate our ability to bring potentially life-saving medicines to people who urgently need effective treatments.” Dr. Huertas, a veteran of the pharmaceutical industry, has extensive experience in research and development and medical and regulatory affairs, especially regarding rare disorders and enzyme replacement therapies.
  • Fund Holdings As of 06/30/2021 Massmutual Equity Opportunities Fund Wellington | T

    Fund Holdings As of 06/30/2021 Massmutual Equity Opportunities Fund Wellington | T

    Fund Holdings As of 06/30/2021 MassMutual Equity Opportunities Fund Wellington | T. Rowe Price Prior to 5/1/2021, the Fund name was MassMutual Select Equity Opportunities Fund. Fund Shares or Par Position Market Security Name Ticker CUSIP Weighting (%) Amount Value ($) Johnson & Johnson JNJ 478160104 3.96 186,089 30,656,302 Diageo PLC DGE 3.77 609,403 29,204,728 Colgate-Palmolive Co CL 194162103 3.76 358,110 29,132,248 TJX Companies Inc TJX 872540109 3.71 426,215 28,735,415 Marsh & McLennan Companies Inc MMC 571748102 3.62 199,196 28,022,893 Northrop Grumman Corp NOC 666807102 3.55 75,623 27,483,667 UnitedHealth Group Inc UNH 91324P102 3.47 67,109 26,873,128 Medtronic PLC MDT G5960L103 3.47 216,366 26,857,512 Chubb Ltd CB H1467J104 3.42 166,664 26,489,576 American Express Co AXP 025816109 3.36 157,512 26,025,708 PepsiCo Inc PEP 713448108 3.32 173,298 25,677,565 Microsoft Corp MSFT 594918104 3.21 91,612 24,817,691 McDonald's Corp MCD 580135101 3.20 107,415 24,811,791 Nike Inc Class B NKE 654106103 3.20 160,556 24,804,296 Coca-Cola Co KO 191216100 2.69 385,636 20,866,764 Fixed Inc Clearing Corp.Repo 0 0 2.51 19,429,520 19,429,520 Union Pacific Corp UNP 907818108 2.43 85,496 18,803,135 Procter & Gamble Co PG 742718109 2.33 133,568 18,022,330 Lockheed Martin Corp LMT 539830109 2.28 46,672 17,658,351 Linde PLC LIN 0 2.28 60,945 17,619,200 Ecolab Inc ECL 278865100 2.07 77,816 16,027,762 Baxter International Inc BAX 071813109 2.02 194,145 15,628,672 Wells Fargo & Co WFC 949746101 1.70 289,900 13,129,571 Accenture PLC Class A ACN G1151C101 1.65
  • What Happened to the Class of 2015? a Comprehensive Follow-Up Study of MCC Graduates

    What Happened to the Class of 2015? a Comprehensive Follow-Up Study of MCC Graduates

    What Happened to the Class of 2015? A Comprehensive Follow-Up Study of MCC Graduates FOLLOW-UP STUDY OF 2015 GRADUATES Table of Contents Introduction & Highlights……………………………. i-ii EMS: Paramedic ....................................................... 103-104 2015 Transfer Colleges ........................................................ 1 Entrepreneurial & Applied Business Studies .......105-106 2015 Employers ..................................................................3-7 Fire Protection Technology .....................................107-108 Summary: Transfer Curriculum (AS)....................... ....... 8 Health Information Technology ..............................109-110 Addictions Counseling ....................................................9-10 Heating, Ventilation, & Air Cond. Tech. ..................111-112 Advertising: Commercial Art ....................................... 11-12 Hospitality Management .......................................... 113-114 Business Administration ..............................................13-15 Human Services ......................................................... 115-116 Cinema & Screen Studies ............................................17-18 Interior Design ........................................................... 117-118 Communication & Media Arts .....................................19-20 Mechanical Technology ...........................................119-120 Computer Information Systems ..................................21-22 Nursing ........................................................................121-122
  • Incyte Corporation 2016 Annual Report

    Incyte Corporation 2016 Annual Report

    2016 ANNUAL REPORT TABLE OF CONTENTS Letter to Shareholders 2 Key Planned Goals for 2017 6 Innovation 7 Growth 10 Strength 13 Corporate Responsibility 15 Company Information 19 ii Incyte’s Executive Management Team LETTER TO SHAREHOLDERS Standing, left to right: Steven H. Stein, MD; Dear Shareholders, Paula J. Swain; Wenqing Yao, PhD; Jonathan E. Dickinson; At Incyte, we believe that innovation and the discovery of new products David W. Gryska; creates long-term value for patients and society, as well as for our employ- Hervé Hoppenot; Michael Morrissey; ees and our shareholders. It is our commitment to these objectives that has Vijay Iyengar, MD enabled us to make significant progress in the last year. During 2016, we saw continued growth in the number of patients being treated with Jakafi® Seated, left to right: Eric H. Siegel, JD, MBA; (ruxolitinib), our JAK1/JAK2 inhibitor, and we also added Iclusig® (ponati- Reid M. Huber, PhD; nib) to our commercial portfolio as part of our European transaction with Barry P. Flannelly, PharmD, MBA ARIAD Pharmaceuticals, Inc. In February 2017, with Eli Lilly & Company, we announced the European approval of Olumiant® (baricitinib). I believe that we are on Summary of Revenue-Generating Products track to reach our goal of PRODUCT NAME DRUG NAME TARGET APPROVED TERRITORY INDICATION(S) becoming a world-class, Jakafi® ruxolitinib1 JAK1/JAK2 Global MF3; PV4 Jakavi® global biopharmaceutical organization. For the first Iclusig® ponatinib BCR-ABL Europe CML and Ph+ ALL5 time in the history of our company, Incyte’s total Olumiant® baricitinib2 JAK1/JAK2 Europe RA6 yearly revenue surpassed $1 billion in 2016.
  • Openair Admin Guide

    Openair Admin Guide

    Admin Guide April 10, 2021 Copyright © 2013, 2021, Oracle and/or its affiliates. This software and related documentation are provided under a license agreement containing restrictions on use and disclosure and are protected by intellectual property laws. Except as expressly permitted in your license agreement or allowed by law, you may not use, copy, reproduce, translate, broadcast, modify, license, transmit, distribute, exhibit, perform, publish, or display any part, in any form, or by any means. Reverse engineering, disassembly, or decompilation of this software, unless required by law for interoperability, is prohibited. The information contained herein is subject to change without notice and is not warranted to be error- free. If you find any errors, please report them to us in writing. If this is software or related documentation that is delivered to the U.S. Government or anyone licensing it on behalf of the U.S. Government, then the following notice is applicable: U.S. GOVERNMENT END USERS: Oracle programs (including any operating system, integrated software, any programs embedded, installed or activated on delivered hardware, and modifications of such programs) and Oracle computer documentation or other Oracle data delivered to or accessed by U.S. Government end users are "commercial computer software" or "commercial computer software documentation" pursuant to the applicable Federal Acquisition Regulation and agency-specific supplemental regulations. As such, the use, reproduction, duplication, release, display, disclosure, modification, preparation of derivative works, and/or adaptation of i) Oracle programs (including any operating system, integrated software, any programs embedded, installed or activated on delivered hardware, and modifications of such programs), ii) Oracle computer documentation and/or iii) other Oracle data, is subject to the rights and limitations specified in the license contained in the applicable contract.
  • Massmutual Mid Cap Growth Fund T

    Massmutual Mid Cap Growth Fund T

    Fund Holdings As of 06/30/2021 MassMutual Mid Cap Growth Fund T. Rowe Price | Frontier Capital Prior to 5/1/2021, the Fund name was MassMutual Select Mid Cap Growth Fund. Fund Shares or Par Position Market Security Name Ticker CUSIP Weighting (%) Amount Value ($) Microchip Technology Inc MCHP 595017104 2.07 1,348,381 201,906,571 Agilent Technologies Inc A 00846U101 1.90 1,252,717 185,164,100 Hologic Inc HOLX 436440101 1.84 2,678,942 178,739,010 Teleflex Inc TFX 879369106 1.82 441,297 177,308,722 Ball Corp BLL 058498106 1.75 2,104,895 170,538,593 Textron Inc TXT 883203101 1.55 2,199,000 151,225,230 Burlington Stores Inc BURL 122017106 1.54 465,929 150,024,479 Catalent Inc CTLT 148806102 1.53 1,376,000 148,773,120 Marvell Technology Inc MRVL 573874104 1.46 2,442,368 142,463,325 Bruker Corp BRKR 116794108 1.39 1,776,000 134,940,480 Ingersoll Rand Inc IR 45687V106 1.29 2,564,000 125,148,840 The Cooper Companies Inc COO 216648402 1.28 314,645 124,684,374 KKR & Co Inc Ordinary Shares KKR 48251W104 1.25 2,050,813 121,490,162 Caesars Entertainment Inc CZR 12769G100 1.13 1,057,315 109,696,431 Reserve Invt Fds 0 76105Y208 1.07 103,877,547 103,877,547 DocuSign Inc DOCU 256163106 1.05 366,000 102,322,620 Chipotle Mexican Grill Inc CMG 169656105 1.04 65,283 101,210,846 Dollar General Corp DG 256677105 1.02 460,009 99,541,348 Veeva Systems Inc Class A VEEV 922475108 1.00 314,189 97,697,070 Avantor Inc AVTR 05352A100 0.98 2,700,000 95,877,000 JB Hunt Transport Services Inc JBHT 445658107 0.98 585,000 95,325,750 KLA Corp KLAC 482480100 0.97 291,710 94,575,299
  • CDER – Redi: Focus on CGMP & FDA Inspections – Participant List

    CDER – Redi: Focus on CGMP & FDA Inspections – Participant List

    FDA – CDER – RedI: Focus on CGMP & FDA Inspections – Participant List These participants granted permission to share their contact information Eileen Zhou Michael Channing A B M Mahfuz ul Alam Research Associate Group Chief - Positron Emission General Manager, Quality Operations Neuralstem Tomography Department ACI HealthCare Limited Germantown, MD, United States NIH Dhaka, Non-US, Bangladesh [email protected] Bethesda, MD, United States [email protected] [email protected] Abe Wong ABHIJEET GUJAR Adam Ebbinghouse CCO Chief Operating Officer QC Associate Gmpsigma SETHU KP Pharmaceutical Technology, Inc. Seattle, WA, United States Porvorim Goa, Non-US, India Bloomington, IN, United States [email protected] [email protected] [email protected] Adil Gatrad Adiseshu Modugula Aditiben Patel Director, Quality Systems RA Regulatory Specialist Actavis MSN USAMMDA Parsippany, NJ, United States Hyderabad, Non-US, India Frederick, MD, United States [email protected] [email protected] [email protected] Adriana de la Cruz ahsanul haque Aimee Gogarty Manager CSO Quality Coordinator Laboratorios Pisa SA de CV FDA Mallinckrodt Jalisco, Non-US, Mexico silver spring, MD, United States Port Allen, LA, United States [email protected] [email protected] [email protected] Aislyn Fronzak Ajay Deshmukh Ajay Khedkar QC Manager QA manager Regulatory Affair PL Developments Ingenus Pharmaceutical Umedica Laboratories Pvt Ltd Clinton, SC, United States Navi mumbai, Non-US, India Mumbai, Non-US, India [email protected]
  • Companies in Attendance

    Companies in Attendance

    COMPANIES IN ATTENDANCE Abbott Diabetes Care Archbow Consulting LLC Business One Technologies Abbott Laboratories ARKRAY USA BusinessOneTech AbbVie Armory Hill Advocates, LLC CastiaRX ACADIA Artia Solutions Catalyst Acaria Health Asembia Celgene Accredo Assertio Therapeutics Celltrion Acer Therapeutics AssistRx Center for Creative Leadership Acorda Therapeutics Astellas Pharma US Inc. Cigna Actelion AstraZeneca Cigna Specialty Pharmacy AdhereTech Athenex Oncology Circassia Advantage Point Solutions Avanir Coeus Consulting Group Aerie Pharmaceuticals Avella Coherus Biosciences AGIOS AveXis Collaborative Associates LLC Aimmune Theraputics Bank of America Collegium Akcea Therapeutics Bausch Health Corsica Life Sciences Akebia Therapeutics Bayer U.S. CoverMyMeds Alder BioPharmaceuticals Becton Dickinson Creehan & Company, Inc., an Inovalon Company Alexion Biofrontera CSL Behring Alkermes Biogen Curant Health Allergan Biohaven CVS Health Almirall BioMarin D2 Consulting Alnylam BioMatrix Specialty Pharmacy Daiichi Sankyo Amarin BioPlus Specialty Pharmacy DBV Technologies Amber Pharmacy Bioventus Deloitte Consulting LLP AmerisourceBergen Blue Cross Blue Shield Association Dendreon Amgen Blue Fin Group Dermira Amicus Therapeutics bluebird bio Dexcom Amneal Boehringer Ingelheim Diplomat Pharmacy Anthem Boston Biomedical Dova Applied Policy Bowler and Company Decision Resources Group Aquestive Therapeutics Braeburn Eisai Arbor Pharmaceuticals Bristol-Myers Squibb 1 electroCore Indivior Merz Pharmaceuticals EMD Serono Inside Rx Milliman Encore Dermatology,
  • 2021 Quarterly Report (Unaudited)

    2021 Quarterly Report (Unaudited)

    JANUARY 31, 2021 2021 Quarterly Report (Unaudited) iShares Trust Table of Contents Page iShares Cohen & Steers REIT ETF.......................................................................................................................................... 3 iShares Core Dividend Growth ETF ........................................................................................................................................ 5 iShares Core High Dividend ETF............................................................................................................................................ 11 iShares Core U.S. REIT ETF ............................................................................................................................................... 14 iShares Dow Jones U.S. ETF ............................................................................................................................................... 17 iShares Global REIT ETF................................................................................................................................................... 29 iShares International Developed Real Estate ETF............................................................................................................................ 34 iShares International Select Dividend ETF................................................................................................................................... 38 iShares Morningstar Large-Cap ETF .......................................................................................................................................
  • Mainstay WMC Enduring Capital Fund Q1 Holdings

    Mainstay WMC Enduring Capital Fund Q1 Holdings

    MainStay MacKay Common Stock Fund Portfolio of Investments January 31, 2021† (Unaudited) Shares Value Common Stocks 98.2% Aerospace & Defense 2.0% Boeing Co. (The) 2,259 $ 438,675 Huntington Ingalls Industries, Inc. 5,380 846,435 Lockheed Martin Corp. 1,121 360,760 Northrop Grumman Corp. 342 98,021 Raytheon Technologies Corp. 6,466 431,476 Textron, Inc. 13,660 618,252 2,793,619 Air Freight & Logistics 0.7% FedEx Corp. 2,381 560,345 United Parcel Service, Inc., Class B 2,108 326,740 887,085 Auto Components 0.1% Aptiv plc 1,149 153,506 Automobiles 1.5% (a) Tesla, Inc. 2,563 2,033,817 Banks 3.6% Bank of America Corp. 14,882 441,251 Comerica, Inc. 14,415 824,538 Fifth Third Bancorp 19,190 555,167 JPMorgan Chase & Co. 5,995 771,377 Signature Bank 5,330 880,463 Synovus Financial Corp. 26,791 996,625 Truist Financial Corp. 10,429 500,383 4,969,804 Beverages 0.2% Coca-Cola Co. (The) 150 7,222 Molson Coors Beverage Co., Class B 3,023 151,634 PepsiCo, Inc. 897 122,503 281,359 Biotechnology 4.4% AbbVie, Inc. 6,231 638,553 Amgen, Inc. 5,750 1,388,222 Biogen, Inc. (a) 4,125 1,165,766 Exelixis, Inc. (a) 2,353 52,260 Gilead Sciences, Inc. 20,056 1,315,674 Incyte Corp. (a) 4,144 371,924 Regeneron Pharmaceuticals, Inc. (a) 751 378,384 United Therapeutics Corp. (a) 4,636 759,470 6,070,253 Building Products 0.6% Carrier Global Corp.